Trial Condition(s):
Hyperphosphatemia, kidney disease
Fosrenol post-marketing surveillance in Japan
Bayer Identifier:
16626
ClinicalTrials.gov Identifier:
EudraCT Number:
Not Available
EU CT Number:
Not Available
Trial Purpose
This study is a regulatory post-marketing surveillance in Japan and it is a local prospective and observational study of patients who have received Fosrenol.
The objective of this research is to collect information on the safety of Fosrenol after its launching, which means collecting information on adverse events, especially adverse events in the digestive system including constipation and serious adverse events, and adverse drug reactions when the drug is administered to the below-mentioned target patients for six months.
The secondary objective is to collect information on the safety of the drug when administered for more than six months, which means collecting information on the safety of the drug when administered for up to 12 months to the target patients who have already been treated with the drug for six months. And also if at the time of 12 months after administration of Lanthanum carbonate the dialysis is not conducted, extending its’ administration will be continued until conduction of dialysis, or until Sept. 30, 2015. The efficacy of fosrenol is evaluated by observing the serum P(phosphorus) level and serum PTH (parathyroid hormone) level change.
Inclusion Criteria
- Patients whom investigators have decided to treat with Lanthanum carbonate for the first time at the respective medical institutions. Those medical institutions have to understand the objective of this investigation and conclude a written contract with Bayer Yakuhin. - The decision to treat patients with Lanthanum carbonate will be made independently by the investigator prior to study inclusion. - Patients treated with Lanthanum carbonate in the indication “Hyperphosphatemia" with chronic kidney disease not on dialysis”.
Exclusion Criteria
- Patients who are contraindicated based on the product label. - Patients who have been already treated with Fosrenol
Trial Summary
Enrollment Goal
Trial Dates
Phase
Could I receive a placebo?
Products
Accepts Healthy Volunteers
Where to Participate
| Locations | |
|---|---|
Locations Investigative Site Many Locations, Japan | Contact Us: E-mail: [email protected] Phone: Not Available |
Trial Design
Drug Use Investigation of Fosrenol for Hyperphosphatemia with chronic kidney disease not on dialysis
Trial Type:
Observational
Intervention Type:
Drug
Trial Purpose:
N/A
Allocation:
N/A
Blinding:
N/A
Assignment:
N/A
Trial Arms:
1
Primary Outcome
- Incidence/number of episodes of adverse drug reactions and adverse eventsTimeframe: 6 months after start of treatment with the drug
Secondary Outcome
- Incidence/number of episodes of adverse drug reactions and adverse eventsTimeframe: until the conduction of dialysis after starting the treatment with Lanthanum carbonate(Maximum 2 years)
- Adverse drug event rate related to the digestive systemTimeframe: until the conduction of dialysis(Maximum 2 years)
- Incidence/number of episodes of adverse events for 6, 12 months ,and from month 13 to the conduction of dialysis after starting the treatment with Lanthanum carbonate.Timeframe: until the conduction of dialysis(Maximum 2 years)
- Incidence/number of episodes of adverse drug reactions for 6, 12 months ,and from month 13 to the conduction of dialysis after starting the treatment with Lanthanum carbonate according to patient characteristics and treatment with Lanthanum carbonate.Timeframe: until the conduction of dialysis(Maximum 2 years)
- Serum P level for six months after start of treatment with the drug in comparison with baseline (at the time of start of treatment with fosrenol)Timeframe: 6 months after start of treatment with the drug
- Serum intact PTH level for six months after start of treatment with the drug in comparison with baselineTimeframe: 6 months after start of treatment with the drug
- Serum P level at 12 months after starting the treatment with Lanthanum carbonate in comparison with baseline (at the time of starting the treatment with Fosrenol).Timeframe: 12 months
- Serum P level at the conduction of dialysis from 13 months after starting the treatment with Lanthanum carbonate in comparison with baseline (at the time of starting the treatment with Fosrenol).Timeframe: until the conduction of dialysis(Maximum 2 years)
- Serum intact PTH level at 12 months after starting the treatment with Lanthanum carbonate in comparison with baseline (at the time of starting the treatment with Lanthanum carbonate).Timeframe: 12 months
- Serum intact PTH level at the conduction of dialysis from 13 months after starting the treatment with Lanthanum carbonate in comparison with baseline (at the time of starting the treatment with Lanthanum carbonate).Timeframe: until the conduction of dialysis(Maximum 2 years)
Additional Information
Copyright © Bayer
Powered by
